(redirected from Doxorubicin hydrochloride)
Also found in: Thesaurus, Medical.


 (lĭp′ə-sōm′, lī′pə-)
A microscopic artificial vesicle consisting of an aqueous core enclosed in phospholipid molecules, used to convey vaccines, drugs, or other substances to target tissues.

lip′o·so′mal adj.


of or relating to liposomes
References in periodicals archive ?
Contract awarded for 2728-2015 list doxorubicin hydrochloride injectable solution or powder for parenteral use 10 mg vial or ampule code 668
Exir Nano Sina Company is another firm which has presented products, including Sina Curcumin 80, Sina Ampholish and liposomal doxorubicin hydrochloride (Sina Doxosome) which was introduced as one of the top three nanoproducts in the country in the 7th Nanotechnology Awards Ceremony in 2014.
Commercial available doxorubicin is a classical chemotherapeutic agent for cancer treatment and its salt, doxorubicin hydrochloride, is highly water soluble and can be good for pharmacological applications (Chabner et al.
Therefore, CAELYX should not be used interchangeably with other formulations of doxorubicin hydrochloride.
In the other 33 patients, doxorubicin hydrochloride or epirubicin hydrochloride (10-20 mg/m2) were injected every 2-4 weeks in a "one-shot" manner.
To combat these odds, Marcus and his colleaues gave high-risk patients -- those with tumors larger than 10 centimeters and evidence of cancer spread -- five cycles of standard chemotherapy consisting of vincristine, cyclophosphamide and doxorubicin hydrochloride.
APP also launched Doxorubicin Hydrochloride Injection, the generic equivalent of Adriamycin([R]), which is owned by Bedford Laboratories GmbH.
Doxorubicin hydrochloride, pegylated liposomal suspension for injection 2 mg / ml, 10 ml vial
Mahnaz Qomi, the CEO of Exir Nano Sina Company, 20mg/10ml injective doxorubicin hydrochloride nano-liposomal anticancer drug, commercially known as Sinadoxosome, was produced in Sobhan Oncology Company and presented to the market for the first time in the Middle-East in 2012 after the acquirement of production permit from the Ministry of Health and Medical Education.
CAELYX is a long-circulating pegylated liposomal formulation of doxorubicin hydrochloride, a widely used cytotoxic agent.
NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced that its hospital-based products business, Abraxis Pharmaceutical Products (APP), has launched Doxorubicin Hydrochloride Injection, USP 2mg/mL, the generic equivalent of Adriamycin([R]) PFS which is owned by Bedford Laboratories, a division of Boehringer Ingelheim GmbH.